β,N,N-Trimethylphenethylamine

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{DISPLAYTITLE:β,N,N-Trimethylphenethylamine}}

{{Infobox drug

| drug_name = β,N,N-Trimethylphenethylamine

| image = β,N,N-Trimethylphenethylamine.svg

| width =

| caption =

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| licence_CA =

| licence_EU =

| DailyMedID =

| licence_US =

| pregnancy_AU =

| pregnancy_category =

| dependency_liability =

| addiction_liability =

| routes_of_administration =

| class =

| ATC_prefix =

| ATC_suffix =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number = 7560-81-8

| CAS_supplemental =

| PubChem = 65295

| PubChemSubstance =

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID = 58784

| UNII =

| KEGG =

| ChEBI =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms = N,N-Dimethyl-2-phenylpropan-1-amine; N,N-DMPPA; DMPPA; β,N,N-TMPEA

| IUPAC_name = N,N-dimethyl-2-phenylpropan-1-amine

| C=11 | H=17 | N=1

| SMILES = CC(CN(C)C)C1=CC=CC=C1

| StdInChI = 1S/C11H17N/c1-10(9-12(2)3)11-7-5-4-6-8-11/h4-8,10H,9H2,1-3H3

| StdInChIKey = JFNWQFWYAAPODB-UHFFFAOYSA-N

}}

β,N,N-Trimethylphenethylamine, also known as N,N-dimethyl-2-phenylpropan-1-amine (N,N-DMPPA or DMPPA) is a monoamine releasing agent of the phenethylamine family.{{cite journal | vauthors = Schindler CW, Thorndike EB, Rice KC, Partilla JS, Baumann MH | title = The Supplement Adulterant β-Methylphenethylamine Increases Blood Pressure by Acting at Peripheral Norepinephrine Transporters | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 369 | issue = 3 | pages = 328–336 | date = June 2019 | pmid = 30898867 | pmc = 6533570 | doi = 10.1124/jpet.118.255976 }} It is the N-methyl derivative of phenpromethamine (β,N-methylphenethylamine) and the N,N-dimethyl derivative of β-methylphenethylamine. The drug is a partial norepinephrine releasing agent, with an {{Abbrlink|EC₅₀|half-maximal effective concentration}} of 1,337{{nbsp}}nM and an {{Abbrlink|E_max|maximal efficacy}} of 67% in rat brain synaptosomes. Conversely, it was inactive on dopamine, whereas serotonin was not reported. The drug produces non-significant increases in blood pressure in rodents, but does not affect heart rate or affect locomotor activity. It may be rapidly metabolized and thereby inactivated. DMPPA was first described in the scientific literature by at least 2019.